Refine by
Hematologic Cancer Equipment & Supplies
25 equipment items found
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T cell to recognize a specific protein that is present on the surface of other cells, including cancer cells. Upon recognition of the target cell via the CAR, the CAR-T cell kills the ...
Manufactured by:TriStar Technology Group LLC based inWashington, DISTRICT OF COLUMBIA (USA)
Molecular Data: No; Approx. # of Donors: 72; Follow Up Data: No; Cores per Donor: 2; Core Size: 1mm; Approx. # of Cores *: 144; TA number: TA3089; Suitable for (IHC or RNA-ISH): IHC; Suitable for CODEX/GeoMx/CosMx: ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy cell leukemia, and Hodgkin’s and certain non-Hodgkin’s lymphomas. In addition to expression on tumor bulk, CD123 expression has been reported on the ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-801 is a structurally novel, oral, small molecule, reversible inhibitor of exportin-1 (XPO1), a nuclear transport protein implicated in both solid tumors and hematologic malignancies. SL-801 has demonstrated preclinical in vitro and in vivo antitumor activity against a wide array of solid and hematologic cancers. SL-801’s potential ...
Manufactured by:The Menarini Group based inFlorence, ITALY
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is highly expressed in a wide range of both solid and hematological cancer cells. Once MEN1309 binds its target, the ...
Manufactured by:MitoImmune Therapeutics Inc. based inGangnam-gu, SOUTH KOREA
MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological cancer with a high incidence and severity of oral mucositis as a side effect of chemoradiation ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
CYNK-001 is the only cryopreserved, allogeneic, off-the-shelf, natural killer (NK) cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid tumors, and infectious disease. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive tumor behavior and poor patient prognosis. Inhibition of XPO1 has been shown to restore tumor suppressor function and proper cell cycle regulation, ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting approaches Adicet is developing are aimed at harnessing the tumor specific ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...
by:Egg Medical, Inc. based inArden Hills, MINNESOTA (USA)
The EggNest™ Radiation Protection System reduces radiation exposure without compromising workflow. The EggNest™ is a comprehensive, scatter radiation protection system fully integrated into the workflow of the modern Cath Lab that helps reduce up to 91% Overall Scatter Radiation Reduction. It provides protection for the entire medical team regardless of location, dramatically reducing ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory B-cell precursor acute lymphoblastic leukemia (ALL) and relapsed / refractory diffuse ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 of <4 nM) that enables transient target engagement for the treatment of hematologic ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines[1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Clofazimine is an orally-active anti-mycobacterial agent with a wide range of anti-mycobacterial activity including leprosy and tuberculosis. Clofazimine exerts anti-inflammatory activities and anti-tumor activities by interfering DNA replication and inhibiting IL2 (IC50 = 1.10 ± 0.26 μM, Jurkat T) production. Clofazimine can be used in mycobacterial and cancer ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to unleash the power of the immune system, including genetically engineered cell ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
We plan to initiate patient screening for a first-in-human Phase 1 study of NTLA-5001, a WT1-directed TCR T cell therapy for the treatment of AML, by the end of 2021. Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed towards the Wilms’ Tumor 1 (WT1) antigen, an over-expressed protein that is often ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 ...